Nanopublications LDF server

Matches in Nanopublications for { <http://purl.org/np/RAV5OTKBYqfQFvqsWTCRUHs3mWgeVUgbhsMLCuQpLLDqc#association> ?p ?o ?g. }

• association type Statement assertion.
• association label "geodon is indicated for the treatment of schizophrenia as monotherapy for the acute treatment of bipolar manic or mixed episodes and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder geodon intramuscular is indicated for acute agitation in schizophrenic patients when deciding among the alternative treatments available for the condition needing treatment the prescriber should consider the finding of ziprasidone s greater capacity to prolong the qt qtc interval compared to several other an tipsychotic drugs prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes type arrhythmia a potentially fatal polymorphic ventricular tachycardia and sudden death in many cases this would lead to the conclusion that other drugs should be tried first whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known see warnings and precautions 5 2 see warnings and precautions 5 2 geodon is an atypical antipsychotic in choosing among treatments prescribers should be aware of the capacity of geodon to prolong the qt interval and may consider the use of other drugs first 5 2 geodon is indicated as an oral formulation for the treatment of schizophrenia 1 1 adults efficacy was established in four 4 6 week trials and one maintenance trial in adult patients with schizophrenia 14 1 acute treatment as monotherapy of manic or mixed episodes associated with bipolar i disorder 1 2 adults efficacy was established in two 3 week trials in adult patients with manic or mixed episodes 14 2 maintenance treatment of bipolar i disorder as an adjunct to lithium or valproate 1 2 adults efficacy was established in one maintenance trial in adult patients 14 2 geodon as an intramuscular injection is indicated for the acute treatment of agitation in schizophrenic patients 1 3 adults efficacy was established in two short term trials in agitated patients with schizophrenia 1 3 geodon is indicated for the treatment of schizophrenia the efficacy of oral ziprasidone was established in four short term 4 and 6 week controlled trials of adult schizophrenic inpatients and in one maintenance trial of stable adult schizophrenic inpatients see clinical studies 14 1 geodon is indicated as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar i disorder efficacy was established in two 3 week monotherapy studies in adult patients see clinical studies 14 2 geodon is indicated as an adjunct to lithium or valproate for the maintenance treatment of bipolar i disorder efficacy was established in a maintenance trial in adult patients the efficacy of geodon as monotherapy for the maintenance treatment of bipolar i disorder has not been systematically evaluated in controlled clinical trials see clinical studies 14 2 geodon intramuscular is indicated for the treatment of acute agitation in schizophrenic patients for whom treatment with ziprasidone is appropriate and who need intramuscular antipsychotic medication for rapid control of agitation the efficacy of intramuscular ziprasidone for acute agitation in schizophrenia was established in single day controlled trials of agitated schizophrenic inpatients see clinical trials 14 1 psychomotor agitation is defined in dsm iv as excessive motor activity associated with a feeling of inner tension schizophrenic patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care e g threatening behaviors escalating or urgently distressing behavior or self exhausting behavior leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation since there is no experience regarding the safety of administering ziprasidone intramuscular to schizophrenic patients already taking oral ziprasidone the practice of co administration is not recommended ziprasidone intramuscular is intended for intramuscular use only and should not be administered intravenously" assertion.
• association object DOID_3312 assertion.
• association predicate treats assertion.
• association subject drugbank:DB00246 assertion.
• association association_type ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.
• association provided_by NeuroDKG assertion.
• association relation TreatmentIndication assertion.